{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:17:14Z","timestamp":1787984234482,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The efficacy of single-fraction 8\u00a0Gy radiotherapy (RT) for achieving hemostasis remains unclear. In this study, we assessed (1) hemostatic efficacy, (2) rebleeding, and (3) factors related to hemostatic efficacy and rebleeding associated with single-fraction 8\u00a0Gy RT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Patients with tumor bleeding who received single-fraction 8\u00a0Gy RT between January 2020 and December 2024 were retrospectively examined. Factors associated with hemostasis and rebleeding (recurrence of bleeding signs\/symptoms, need for red blood cell [RBC] transfusion or salvage treatment after confirmation of hemostasis or decreasing hemoglobin levels) were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 90 lesions in 82 patients were examined. The median follow-up time after the administration of RT treatment was 80\u00a0days (interquartile range [IQR], 35\u2013206\u00a0days; range, 7\u2013776\u00a0days). The overall hemostatic ratio of lesions within 30\u00a0days (=\u200930-day hemostatic response rate) was 68.9%. In an exploratory analysis, gastroduodenal (gastrointestinal [GI]-gastroduodenal) bleeding showed a higher 30-day hemostatic response than GI-non-gastroduodenal and non-GI sites (80.4% vs. 56.8%; odds ratio, 3.08; 95% confidence interval [CI], 1.12\u20139.09;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Additionally, among evaluable patients with or without rebleeding (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200952), the median time to rebleeding after hemostasis was 102\u00a0days (95% CI, 69\u2013196\u00a0days). The cumulative rebleeding rates at 30 and 60\u00a0days after hemostasis were 11.8% and 24.1%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although this study includes patients with different cancer types, bleeding sites, and treatment backgrounds, single-fraction 8\u00a0Gy RT demonstrated potential hemostatic benefit for tumor bleeding in the palliative setting. Our findings should be interpreted cautiously because of the retrospective nature of this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-026-02061-y","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:51:28Z","timestamp":1787982688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemostatic single-fraction 8\u00a0Gy radiotherapy for tumor bleeding: a single-centre retrospective study"],"prefix":"10.1007","author":[{"given":"Kenji","family":"Makita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenari","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadamoto","family":"Zenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"2061_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.radonc.2011.01.009","volume":"98","author":"L van Lonkhuijzen","year":"2011","unstructured":"van Lonkhuijzen L, Thomas G. Palliative radiotherapy for cervical carcinoma, a systematic review. Radiother Oncol. 2011;98:287\u201391. https:\/\/doi.org\/10.1016\/j.radonc.2011.01.009.","journal-title":"Radiother Oncol"},{"key":"2061_CR2","doi-asserted-by":"publisher","first-page":"25797","DOI":"10.18632\/oncotarget.15554","volume":"8","author":"J Tey","year":"2017","unstructured":"Tey J, Soon YY, Koh WY, et al. Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:25797\u2013805. https:\/\/doi.org\/10.18632\/oncotarget.15554.","journal-title":"Oncotarget"},{"key":"2061_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.prro.2011.01.005","volume":"1","author":"G Rodrigues","year":"2011","unstructured":"Rodrigues G, Videtic GM, Sur R, et al. Palliative thoracic radiotherapy in lung cancer: an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2011;1:60\u201371. https:\/\/doi.org\/10.1016\/j.prro.2011.01.005.","journal-title":"Pract Radiat Oncol"},{"key":"2061_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.brachy.2006.05.001","volume":"5","author":"YC Ung","year":"2006","unstructured":"Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK, et al. The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small-cell lung cancer: a systematic review. Brachytherapy. 2006;5:189\u2013202. https:\/\/doi.org\/10.1016\/j.brachy.2006.05.001.","journal-title":"Brachytherapy"},{"key":"2061_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/026921639200600112","volume":"6","author":"C Regnard","year":"1992","unstructured":"Regnard C, Makin W. Management of bleeding in advanced cancer-a flow diagram. Palliat Med. 1992;6:74\u20138. https:\/\/doi.org\/10.1177\/026921639200600112.","journal-title":"Palliat Med"},{"key":"2061_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctro.2018.11.007","volume":"14","author":"LG Sapienza","year":"2019","unstructured":"Sapienza LG, Ning MS, Jhingran A, et al. Short-course palliative radiation therapy leads to excellent bleeding control: a single center retrospective study. Clin Transl Radiat Oncol. 2019;14:40\u20136. https:\/\/doi.org\/10.1016\/j.ctro.2018.11.007.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2061_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10120-021-01254-w","volume":"25","author":"T Saito","year":"2022","unstructured":"Saito T, Kosugi T, Nakamura N, et al. Treatment response after palliative radiotherapy for bleeding gastric cancer: a multicenter prospective observational study (JROSG 17-3). Gastric Cancer. 2022;25:411\u201321. https:\/\/doi.org\/10.1007\/s10120-021-01254-w.","journal-title":"Gastric Cancer"},{"key":"2061_CR8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/jjco\/hyy054","volume":"48","author":"N Nakamura","year":"2018","unstructured":"Nakamura N, Kawamori J, Takahashi O, et al. Palliative radiotherapy for breast cancer patients with skin invasion: a multi-institutional prospective observational study. Jpn J Clin Oncol. 2018;48:555\u20138. https:\/\/doi.org\/10.1093\/jjco\/hyy054.","journal-title":"Jpn J Clin Oncol"},{"key":"2061_CR9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ijrobp.2023.02.008","volume":"116","author":"S Chatterjee","year":"2023","unstructured":"Chatterjee S, Chakrabarty S, Santosham R, et al. Alleviating morbidity from locally advanced breast cancer using a practical and short radiation therapy regimen: results of the HYPORT palliative studies. Int J Radiat Oncol Biol Phys. 2023;116:1033\u201342. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.02.008.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2061_CR10","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1200\/JCO.2007.15.3312","volume":"26","author":"A Fairchild","year":"2008","unstructured":"Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008;26:4001\u201311. https:\/\/doi.org\/10.1200\/JCO.2007.15.3312.","journal-title":"J Clin Oncol"},{"key":"2061_CR11","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/cas.12466","volume":"105","author":"JT Ma","year":"2014","unstructured":"Ma JT, Zheng JH, Han CB, Guo QY. Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer. Cancer Sci. 2014;105:1015\u201322. https:\/\/doi.org\/10.1111\/cas.12466.","journal-title":"Cancer Sci"},{"key":"2061_CR12","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1016\/j.clon.2023.06.007","volume":"35","author":"J Song","year":"2023","unstructured":"Song J, Brown C, Dennis K, Gaudet M, Haddad A. Palliative radiotherapy for hemostasis in malignancy: a systematic review. Clin Oncol (R Coll Radiol). 2023;35:e478\u201388. https:\/\/doi.org\/10.1016\/j.clon.2023.06.007.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2061_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.radonc.2022.06.002","volume":"173","author":"E Oldenburger","year":"2022","unstructured":"Oldenburger E, Brown S, Willmann J, et al. ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. Radiother Oncol. 2022;173:240\u201353. https:\/\/doi.org\/10.1016\/j.radonc.2022.06.002.","journal-title":"Radiother Oncol"},{"key":"2061_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.radonc.2022.05.024","volume":"173","author":"J van der Velden","year":"2022","unstructured":"van der Velden J, Willmann J, Spa\u0142ek M, et al. ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. Radiother Oncol. 2022;173:197\u2013206. https:\/\/doi.org\/10.1016\/j.radonc.2022.05.024.","journal-title":"Radiother Oncol"},{"key":"2061_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","volume":"112","author":"R Timmerman","year":"2022","unstructured":"Timmerman R. A story of hypofractionation and the table on the wall. Int J Radiat Oncol Biol Phys. 2022;112:4\u201321. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.09.027.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2061_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"2061_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13014-021-01884-5","volume":"16","author":"J Lee","year":"2021","unstructured":"Lee J, Byun HK, Koom WS, Lee YC, Seong J. Efficacy of radiotherapy for gastric bleeding associated with advanced gastric cancer. Radiat Oncol. 2021;16:161. https:\/\/doi.org\/10.1186\/s13014-021-01884-5.","journal-title":"Radiat Oncol"},{"key":"2061_CR18","doi-asserted-by":"publisher","first-page":"20190958","DOI":"10.1259\/bjr.20190958","volume":"93","author":"O Tanaka","year":"2020","unstructured":"Tanaka O, Sugiyama A, Omatsu T, Tawada M, Makita C, Matsuo M. Hemostatic radiotherapy for inoperable gastric cancer: a pilot study. Br J Radiol. 2020;93:20190958. https:\/\/doi.org\/10.1259\/bjr.20190958.","journal-title":"Br J Radiol"},{"key":"2061_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12904-015-0034-y","volume":"14","author":"C Kondoh","year":"2015","unstructured":"Kondoh C, Shitara K, Nomura M, et al. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. BMC Palliat Care. 2015;14:37. https:\/\/doi.org\/10.1186\/s12904-015-0034-y.","journal-title":"BMC Palliat Care"},{"issue":"2","key":"2061_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/2050640614522619","volume":"2","author":"CJ Corte","year":"2014","unstructured":"Corte CJ, Burger DC, Horgan G, Bailey AA, East JE. Postpolypectomy haemorrhage following removal of large polyps using mechanical haemostasis or epinephrine: a meta-analysis. United European Gastroenterol J. 2014;2(2):123\u201330. https:\/\/doi.org\/10.1177\/2050640614522619.","journal-title":"United European Gastroenterol J"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02061-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-02061-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-02061-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:51:29Z","timestamp":1787982689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-02061-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":20,"alternative-id":["2061"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-02061-y","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S. Z. reports receiving consulting fee from Eisai Co., Ltd., Maruho Co., Ltd, Maruishi Pharmaceutical Co. Ltd, CMIC HOLDINGS Co., Ltd., Shin Nippon Yakugyo Co., Ltd., Daiichi Sankyo, Limited, and Ayumi Pharmaceutical Corporation; and honoraria from Taiho Pharmaceutical, Eisai Co., Ltd., Merck Biopharma Co., Ltd, Bristol-Myers Squibb K.K., Maruho Co., Ltd, Ono pharmaceutical, Sanwa, Agaku Kenkyusho, LTD., Maruishi Pharmaceutical Co. Ltd, Zeria Pharmaceutical Co., Ltd. Bayer Yakuhin, Ltd., MSD K.K, NUTRI Co., Ltd., Rakuten Medical, Inc, Stratpharma AG, and Daiichi Sankyo, Limited. M. N. reports receiving research funding from Illumina; honoraria from AstraZeneca, Illumina, Kyowa Kirin and Sumitomo Heavy Industries. All other authors declare that they have no conflict of interest. M.W. reports receiving honoraria from Nihon Medi-Physics Co.,Ltd. and Kyowa Kirin Co., Ltd..All other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the Institutional Research Committee and the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board in National Cancer Center, Japan (No. 2017-440), and the consent was waved because of the retrospective nature of this study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}